While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > COLUMN
COLUMN
- Sun Tzu and the Art of Interviewing
March 18, 2014
- 2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
- The Time Is Now for Medical Affairs
January 17, 2014
- Blue Ocean Recruiting
December 20, 2013
- Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
- A World of Opportunity for the Brave
November 1, 2013
- Does HR Have an Image Problem?
September 20, 2013
- Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
- Watch out for the Gorilla when Hiring Talent
July 19, 2013
- Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
- Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
- An Insider’s Perspective on Hiring in Japan
April 26, 2013
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…